Halozyme Therapeutics (HTI) Misses Q4 EPS by 1c
More News related to HTI
- Halozyme Therapeutics (HTI) Adopts SEC Rule 10b5-1 Policy
- Halozyme Therapeutics (HTI) Misses Q4 EPS by 1c
- StreetInsider.com Pre-Open Movers 12/06
- Halozyme Therapeutics (HTI) Soars on Deal with Roche
- Halozyme Therapeutics (HTI) Announces Agreement with Roche for the Application of Enhanze
More News related to Earnings
- Nanosphere (NSPH) Receives 510(k) from U.S. FDA to Update RVNATSP to Include Flu Cultured Clinical Isolates with H1N1 Virus
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
Halozyme Therapeutics, Inc. (Amex: HTI) reports a Q4 loss of $0.07, 1 cent worse than estimates. Revenues were $426,000 vs. $210,000 consensus.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
